Atara biotherapeutics' ebvallo™ (tabelecleucel) wins prix galien international award for best product for orphan/rare diseases

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that ebvallotm (tabelecleucel or tab-cel®) has been awarded the prestigious 2024 prix galien international award for “best product for orphan/rare diseases.” the award was presented to pierre fabre laborato.
ATRA Ratings Summary
ATRA Quant Ranking